Cabazitaxel and Radiation For Patients With Prostate Cancer

Conditions for Patient Eligibility Each patient must meet all of the following inclusion criteria to be enrolled in the study: * Radical prostatectomy for adenocarcinoma of the prostate with at least one of the following: * Extracapsular tumor extension, * Positive surgical margins, * Seminal vesicle invasion * Regional lymph node positive (N1) * Post-prostatectomy PSA of \> 0.1 - \< 2.0 ng/mL at least 6 weeks after prostatectomy and within 30 days of registration in a patient with T2 or T3 disease at prostatectomy. * No distant metastases. * No prior pelvic or prostate radiation or chemotherapy for prostate cancer. * ECOG performance status 0-1. * Age\>18. * Required entry laboratory parameters within 14 days of study entry: Granulocytes ≥ 1500 cells/mm3; platelet count ≥100,000 cells/mm3, Creatinine ≤ 1.5X upper limit of normal (if creatinine clearance 1.0-1.5x ULN, creatinine clearance will be calculated according to Chronic Kidney Disease Epidemiology Group formula and patients with creatinine clearance \< 60 ml/min should be excluded),19 .Hgb \> 9.0 g/dl, total bilirubin ≤ 1x ULN, and AST or ALT ≤ 2.5 x ULN. * Life expectancy of at least 1 year. * Must not have uncontrolled severe, intercurrent illness. * No concurrent anticancer therapy. * Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter. * Signed study-specific consent form prior to study entry. * Conditions for Patient Ineligibility Patients meeting any of the following exclusion criteria are not to be enrolled in the study: * Evidence of distant metastases (M1). Equivocal bone scans are allowed if plain films are negative for metastasis. * Major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up. * Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years (For example, carcinoma in situ of the oral cavity or bladder are permissible). * History of severe hypersensitivity (\> grade 3) reaction to Cabazitaxel or other drugs formulated with polysorbate 80. * History of severe hypersensitivity (\> grade 3) to docetaxel. * Any uncontrolled severe, intercurrent illness (including uncontrolled diabetes) * At least 4 weeks since any major surgery. * Patients on concurrent anticancer therapy. * PSA \> 2ng/ml * Concurrent or planned treatment with strong inhibitors or inducers of cytochrome p450 3A4/5 (a one-week wash out period is necessary for patients who are already on these treatments (see appendix H and I) * Androgen deprivation therapy started prior to prostatectomy for \> 6 months duration; * Neoadjuvant chemotherapy prior to prostatectomy; * Prior cryosurgery or brachytherapy of the prostate; prostatectomy should be the primary treatment and not a salvage procedure; * Prior pelvic radiotherapy;